The Cuban capital is facing a complex Covid 19 spread, with numbers on the rise surpassing 200 confirmed cases on Friday, which has led local authorities to call for harder work against the disease.

Cuba has set up a multi-disciplinary expert team to research on genetic variants of the SARS-COV 2 virus, which causes the Covid 19 disease.

The general director of the Finlay Vaccine Institute (IFV), Vicente Verez Bencomo, announced that Cuba is creating the capacity for the production of one hundred million doses of the injectable vaccine Soberana 02, against COVID-19.

Cuba reported the presence of a new genetic variant of SARS-CoV-2 , previously detected in South Africa and which so far has spread to 20 countries, stated today Dr. Maria Guadalupe Guzman Tirado, head of the Research, Diagnosis and Reference Unit of the Pedro Kouri Institute of Tropical Medicine (IPK).

Cuba studied for COVID-19 , 13, 449 samples, resulting in 530 positive ones. The country accumulates 1,738,190 samples tested and 20,060 positive.

Cuba studied for COVID-19, 11, 433 samples, resulting in 408 positive ones. The country accumulates 1,736,174 samples taken and 19,530 positive.

An update on the management and control of Leprosy in Cuba will be released January 28 and 29 during an online workshop with prestiged dermatologists.

Cuba studied 10, 931 samples to detect COVID 19, resulting in 349 new cases. There are accumulated 1, 724, 741 samples carried and 19, 122 positive (1.11%).

Since Monday night, an antigen test began to be applied in polyclinics and hospitals of the capital to patients with symptoms suggestive of COVID-19.

A novel antigen test that would allow the early identification of those infected with the SARS CoV-2 coronavirus is in the validation process in Matanzas(west Cuba), according to what was revealed during a meeting of the Provincial Defense Council (CDP).

Cuba studied for COVID-19, 12, 676 new samples, resulting 330 positive ones. The country accumulates 1, 713, 810 of samples carried out and 18, 773 positive (1,09%).

Fatigue, psychological and pulmonary alterations, compatible with chronic renal damage and a persistent inflammatory response are some of the sequels caused by COVID-19, explained Daniel González Rubio, specialist in Internal Medicine at the Pedro Kourí Institute of Tropical Medicine (IPK).

 The clinical trials of the two vaccine candidates developed in the Center for Genetic Engineering and Biotechnology (CIGB) of Cuba concluded the short cycle of its phase I.

Cuba studied 11,387 samples for COVID-19, with 292 positive tests. The country accumulates 1 ,701, 134 samples made and 18, 443 positive ones (1.8%).